CoChat

Masitinib for the Treatment of Alzheimer’s Disease

Ettcheto, Miren, Cano, Amanda, Sanchez-López, Elena, Verdaguer, Ester, Folch, Jaume, Auladell, Carme, Camins, Antoni · 2021 · Neurodegenerative Disease Management

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

Abstract

The actual standard treatment for mild-to-moderately severe Alzheimer's disease only attacks its symptoms. Masitinib is a potent and selective phenylaminothiazole-type tyrosine kinase inhibitor which is currently in Phase III studies for the treatment of Alzheimer's disease (AD) with the aim of modifying its evolution and with multiple pharmacological targets such as inhibition of mast cells activity, inhibition of microglia activation, modulation of Aβ and Tau protein signaling pathway and prevention of synaptic damage. Here, we review the preclinical and clinical studies that investigated the administration of masitinib treatment in monotherapy in AD. All research studies revealed positive effects concerning the cognitive functions in AD and generally with good safety and tolerability.

Overview

Integrity signals

Registry

Crossref · 10.2217/nmt-2021-0019

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 86 references

Research works printed but not linked: 6

  1. 10.1186/s40478-020-00976-9 · DOI · Paper page
  2. 10.1371/journal.pone.0007258 · DOI · Paper page
  3. AB Science press release. (2020). https://www.ab-science.com/results-from-phase-2b-3-studyevaluating-masitinib-in-alzheimers-disease/
  4. 10.1523/JNEUROSCI.4162-03.2004 · DOI · Paper page
  5. 10.1523/JNEUROSCI.22-01-00010.2002 · DOI · Paper page
  6. 10.1016/j.cell.2010.06.036 · DOI · Paper page

Cited by

See all 29

Metadata

Authors
Ettcheto, M., Cano, A., Sanchez-López, E., Verdaguer, E., Folch, J., Auladell, C., & Camins, A.
Affiliations
  • Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
  • Universitat Internacional de Catalunya (ES)
  • Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED) Madrid Spain
  • Universitat de Barcelona (ES)
Venue
Neurodegenerative Disease Management
Published
2021-08
Volume
11
Issue
4
Pages
263-276
ISSN
  • 1758-2024 (ISSN-L)
  • 1758-2032
OpenAlex
W3194662903
Cited by
28
References
86
Citations by year
2026: 4 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 7
FWCI
0.63
Type
journal article
Language
en
Open access
closed
Locations
  • Neurodegenerative Disease Management (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
masitinib, Alzheimer's disease, tyrosine kinase inhibitors, mast cell inhibition, microglial activation, amyloid-beta, tau protein, synaptic damage, cognitive function, drug safety and tolerability
MeSH terms
Alzheimer Disease, Benzamides, Cognition, Humans, Piperidines, Pyridines, Thiazoles, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Masitinib for the Treatment of Alzheimer’s Disease. https://app.cochat.ai/papers/10.2217/nmt-2021-0019
The paper
Ettcheto, M., Cano, A., Sanchez-López, E., Verdaguer, E., Folch, J., Auladell, C., & Camins, A. (2021). Masitinib for the Treatment of Alzheimer’s Disease. Neurodegenerative Disease Management. https://doi.org/10.2217/nmt-2021-0019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.